Friendswood, Texas, April 10, 2024–(BUSINESS WIRE)–Castle Biosciences, Inc. (NASDAQ:CSTL), a company that improves health through innovative tests that guide patient care, announced today that Frank Stokes, the company's chief financial officer, He made the following announcement for the second consecutive year: was named one of Houston's Top 25 CFOs by TOP CFO (formerly Finance and Investments). This annual award recognizes the most outstanding CFOs by region, selected for their skills in leading complex financial functions and their ability to drive growth and profitability as influential financial leaders in their communities. It is something to do.
“We are proud of Frank for earning the No. 2 spot among Houston's top 25 CFOs,” said Derek Metsholt, President and CEO of Castle Biosciences. “In a dynamic and competitive city like Houston, this recognition is a testament to Frank's financial leadership in our company's growth and development.”
Mr. Stokes has served as Castle's Chief Financial Officer since December 2017. Ms. Stokes holds a Bachelor of Business Administration and a Juris Doctorate and her MBA degree from the University of North Carolina at Chapel Hill.
A comprehensive list of Houston's Top 25 CFOs for 2024 can be found here.
About Castle Bioscience
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company that improves health through innovative tests that guide patient care. The company aims to transform disease management by putting people first: patients, clinicians, employees and investors.
Castle's current portfolio consists of tests for skin cancer, Barrett's esophagus, mental health conditions, and uveal melanoma. In addition, we are developing tests for other diseases with high clinical need, including tests in development to help select systemic therapies for patients with moderate to severe atopic dermatitis, psoriasis, and related diseases. We also have an active research and development program in testing. For more information, please visit www.CastleBiosciences.com, LinkedIn, Facebook, X And Instagram.
DecisionDx-Melanoma, DecisionDx-CMsequenceDecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME, and DecisionDx-UMsequence is a trademark of Castle Biosciences, Inc.
TOP About CFO
TOP CFOs (formerly Finance & Investing) is a comprehensive source of research and information, business news, and corporate activities related to banking, finance, public and private markets, and other topics related to CFOs. Based in New York City, the company is led by an experienced team of editors, writers, and media professionals with expertise in finance and capital markets.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240410056539/ja/
contact address
Investor contact information:
Camila Zucchero
czuckero@castlebiosciences.com
Media contact:
Alison Marshall
amarshall@castlebiosciences.com
